Avadel Pharmaceuticals (AVDL)
NASDAQ: AVDL
· Real-Time Price · USD
13.47
-0.22 (-1.61%)
At close: Aug 18, 2025, 3:59 PM
13.48
0.04%
After-hours: Aug 18, 2025, 06:30 PM EDT
-1.61% (1D)
| Bid | 13.31 |
| Market Cap | 1.3B |
| Revenue (ttm) | 194.45M |
| Net Income (ttm) | -26.41M |
| EPS (ttm) | -0.02 |
| PE Ratio (ttm) | -673.75 |
| Forward PE | 15.72 |
| Analyst | Buy |
| Ask | 14.1 |
| Volume | 727,331 |
| Avg. Volume (20D) | 1,492,581.5 |
| Open | 13.83 |
| Previous Close | 13.69 |
| Day's Range | 13.40 - 13.91 |
| 52-Week Range | 6.38 - 16.66 |
| Beta | 1.47 |
About AVDL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AVDL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AVDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Avadel Pharmaceuticals is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+14.77%
Avadel Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
3 months ago
+9.61%
Avadel Pharmaceuticals shares are trading higher after the company raised its FY25 sales guidance.
1 week ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Th...
1 month ago · businesswire.com
ASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersGREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceutic...
